Earnings

Repligen Raises FY2026 Adj EPS Guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 Est; Raises FY2026 Sales Guidance from $813.000M-$835.000M to $844.000M-$852.000M vs $829.693M Est

Oct 27, 2026 · 07:01 AM ET· updated 2h ago

Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 analyst estimate. Raises FY2026 sales outlook from $813.000 million-$835.000 million to $844.000 million-$852.000 million vs

Why It Matters

Repligen raised its sales forecast and profit target for next year. This suggests the company is more confident about its business growth ahead.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

RGEN172.79

-7.38 (-4.10%)

MMM172.33

-0.46 (-0.27%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.